BOOK
Current MR Imaging of Breast Cancer, An Issue of Magnetic Resonance Imaging Clinics of North America, E-Book
(2018)
Additional Information
Book Details
Abstract
This issue of MRI Clinics of North America focuses on Current MR Imaging of Breast Cancer, and is edited by Dr. Jessica Leung. Articles will include: Breast MRI: Atlas of anatomy, physiology, pathophysiology, and BI-RADS lexicon; Neoadjuvant therapy monitoring, including inflammatory breast cancer; Breast MRI biopsy considerations: Technique, histologic upgrading, and radiologic-pathologic concordance; Breast MRI techniques and developments: 1.5 vs 3T, diffusion, fast MRI, PET-MRI, and other developing techniques; ACR Accreditation, Performance Metrics, Reimbursement, and Economic Considerations in Breast MRI; Screening: high-risk and dense breasts, especially compared with tomosynthesis and ultrasound; Extent of breast disease, especially compared with tomosynthesis and ultrasound, with special focus on nodal assessment; Problem-solving tool for imaging finding and clinical symptoms of breast cancer; MRI compared with contrast-enhanced mammography; MRI compared with molecular breast imaging; MRI compared with positron emission mammography; How does MRI help care for my breast cancer patient? Perspective of a surgical oncologist; How does MRI help care for my breast cancer patient? Perspective of a medical oncologist; How does MRI help care for my breast cancer patient? Perspective of a radiation oncologist; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Current MR Imaging ofBreast Cancer | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Foreword: Breast MR Imaging | v | ||
| Preface: Breast MR Imaging in Era of Value-Based Medicine | v | ||
| Breast MR Imaging: Atlas of Anatomy, Physiology, Pathophysiology, and Breast Imaging Reporting and Data Systems Lexicon | v | ||
| Role of MR Imaging for the Locoregional Staging of Breast Cancer | v | ||
| Role of MR Imaging in Neoadjuvant Therapy Monitoring | v | ||
| Problem-Solving MR Imaging for Equivocal Imaging Findings and Indeterminate Clinical Symptoms of the Breast | v | ||
| MR Imaging–Guided Breast Interventions: Indications, Key Principles, and Imaging-Pathology Correlation | vi | ||
| Developments in Breast Imaging: Update on New and Evolving MR Imaging and Molecular Imaging Techniques | vi | ||
| Comparison of Contrast-Enhanced Mammography and Contrast-Enhanced Breast MR Imaging | vi | ||
| Use of Breast-Specific PET Scanners and Comparison with MR Imaging | vi | ||
| Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment ... | vii | ||
| How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist | vii | ||
| How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist | vii | ||
| How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Radiation Oncologist | vii | ||
| American College of Radiology Accreditation, Performance Metrics, Reimbursement, and Economic Considerations in Breast MR I ... | viii | ||
| MAGNETIC RESONANCE IMAGINGCLINICS OF NORTH AMERICA | ix | ||
| CME Accreditation Page | x | ||
| PROGRAM OBJECTIVE | x | ||
| TARGET AUDIENCE | x | ||
| LEARNING OBJECTIVES | x | ||
| ACCREDITATION | x | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | x | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | x | ||
| TO ENROLL | x | ||
| METHOD OF PARTICIPATION | x | ||
| CME INQUIRIES/SPECIAL NEEDS | x | ||
| Foreword:Breast MR Imaging | xi | ||
| Preface:Breast MR Imaging in Era of Value-Based Medicine | xiii | ||
| Breast MR Imaging\rAtlas of Anatomy, Physiology,\rPathophysiology, and Breast Imaging\rReporting and Data Systems Lexicon | 179 | ||
| Key points | 179 | ||
| INTRODUCTION | 179 | ||
| ANATOMY | 179 | ||
| THE MR IMAGING BREAST IMAGING REPORTING AND DATA SYSTEMS LEXICON | 180 | ||
| BREAST TISSUE | 180 | ||
| BREAST LESIONS | 181 | ||
| Focus | 181 | ||
| Mass | 182 | ||
| Nonmass Enhancement | 182 | ||
| Benign and Nonenhancing Findings | 183 | ||
| Associated Features | 184 | ||
| KINETIC CURVE ASSESSMENT | 185 | ||
| IMPLANT ASSESSMENT | 188 | ||
| FINAL ASSESSMENT | 189 | ||
| SUMMARY | 190 | ||
| REFERENCES | 190 | ||
| Role of MR Imaging for the Locoregional Staging of Breast Cancer | 191 | ||
| Key points | 191 | ||
| INTRODUCTION | 191 | ||
| Multifocality and Multicentricity of Breast Cancer | 191 | ||
| MR IMAGING DETECTION OF ADDITIONAL DISEASE IN THE IPSILATERAL BREAST | 192 | ||
| CONTRALATERAL DISEASE | 193 | ||
| MR IMAGING COMPARED WITH DIGITAL BREAST TOMOSYNTHESIS FOR LOCAL STAGING | 194 | ||
| MR IMAGING EVALUATION OF NODAL BASINS | 195 | ||
| IMPACT OF BREAST MR IMAGING ON SURGICAL OUTCOMES | 196 | ||
| IMPACT OF MR IMAGING ON MASTECTOMY RATES | 198 | ||
| INVASIVE LOBULAR CARCINOMA | 198 | ||
| Ductal Carcinoma In Situ and Extensive Intraductal Component | 199 | ||
| IMPACT OF MR IMAGING ON RECURRENCE RATES | 200 | ||
| OF MOLECULAR SUBTYPES | 201 | ||
| SUMMARY | 201 | ||
| REFERENCES | 201 | ||
| Role of MR Imaging in Neoadjuvant Therapy Monitoring | 207 | ||
| Key points | 207 | ||
| INTRODUCTION | 207 | ||
| ASSESSMENT OF RESPONSE BY CONVENTIONAL IMAGING | 208 | ||
| IMAGING | 209 | ||
| MR IMAGING PROTOCOL | 209 | ||
| IMAGING SIZE | 209 | ||
| IMAGING MORPHOLOGY | 211 | ||
| IMAGING KINETICS | 212 | ||
| RESPONSE ASSESSMENT USING OTHER MR IMAGING FEATURES | 214 | ||
| IMAGING BY BREAST CANCER SUBTYPE | 215 | ||
| IMAGING IN INFLAMMATORY BREAST CANCER | 215 | ||
| SUMMARY | 217 | ||
| REFERENCES | 217 | ||
| Problem-Solving MR Imaging for Equivocal Imaging Findings and Indeterminate Clinical Symptoms of the Breast | 221 | ||
| Key points | 221 | ||
| INTRODUCTION | 221 | ||
| CLINICAL SYMPTOMS | 222 | ||
| Palpable Lump | 222 | ||
| Breast Pain (Mastodynia) | 222 | ||
| Nipple Discharge | 223 | ||
| EQUIVOCAL IMAGING FINDINGS | 224 | ||
| Mass | 224 | ||
| Calcifications | 224 | ||
| Architectural Distortion | 226 | ||
| Asymmetry | 227 | ||
| Empirical data | 228 | ||
| Surgical scar | 228 | ||
| LIMITATIONS | 229 | ||
| SUMMARY | 229 | ||
| REFERENCES | 229 | ||
| MR Imaging–Guided Breast Interventions | 235 | ||
| Key points | 235 | ||
| INTRODUCTION | 235 | ||
| INDICATIONS FOR MR IMAGING–GUIDED BREAST INTERVENTIONS | 235 | ||
| PREPROCEDURE EVENTS | 236 | ||
| Procedure Planning | 236 | ||
| Patient Preparation and Risks | 236 | ||
| STEPS COMMON TO ALL MR IMAGING–GUIDED BREAST INTERVENTIONS | 237 | ||
| Positioning | 237 | ||
| Targeting | 237 | ||
| Intervention | 237 | ||
| Postintervention Care | 237 | ||
| MR IMAGING–GUIDED BIOPSY | 238 | ||
| Place the Biopsy Device | 239 | ||
| Sampling | 239 | ||
| Confirm the Adequacy of Sampling | 240 | ||
| Approach to Difficult Lesions | 240 | ||
| MR IMAGING–GUIDED CLIP PLACEMENT | 240 | ||
| MR IMAGING–GUIDED NEEDLE LOCALIZATION | 240 | ||
| IMAGING-PATHOLOGY CORRELATION AFTER MR IMAGING–GUIDED BIOPSY | 242 | ||
| Management of Lesions with Imaging-Concordant Benign Pathology Results | 243 | ||
| Management of Lesions with Imaging-Concordant High-Risk Pathology Results | 244 | ||
| SUMMARY | 244 | ||
| REFERENCES | 245 | ||
| Developments in Breast Imaging | 247 | ||
| Key points | 247 | ||
| INTRODUCTION | 247 | ||
| MR IMAGING | 247 | ||
| Magnetic Field Strength: 3 T Versus 1.5 T | 248 | ||
| MR imaging protocol at 3 T | 248 | ||
| Advantages of 3 T imaging | 248 | ||
| Disadvantages of 3 T imaging | 248 | ||
| Diffusion-Weighted Imaging | 248 | ||
| Technical considerations | 249 | ||
| Clinical use | 249 | ||
| Monitoring neoadjuvant chemotherapy | 249 | ||
| Evaluation of the axilla | 249 | ||
| Abbreviated MR Imaging | 250 | ||
| Abbreviated MR Imaging protocols | 250 | ||
| Upcoming clinical trials and future directions | 252 | ||
| Molecular Imaging Techniques | 252 | ||
| Breast-specific γ-imaging | 252 | ||
| Positron emission mammography | 253 | ||
| PET and MR Imaging | 253 | ||
| PET and MR imaging and the evaluation of breast lesions | 254 | ||
| PET and MR imaging, and known disease | 254 | ||
| Local tumor staging | 254 | ||
| Distant metastatic disease | 254 | ||
| Treatment response | 255 | ||
| Technical challenges | 255 | ||
| SUMMARY | 255 | ||
| ACKNOWLEDGMENTS | 255 | ||
| REFERENCES | 255 | ||
| Comparison of Contrast-Enhanced Mammography and Contrast-Enhanced Breast MR Imaging | 259 | ||
| Key points | 259 | ||
| INTRODUCTION | 259 | ||
| IMAGING TECHNIQUE | 259 | ||
| IMAGING PROTOCOL | 260 | ||
| MAMMOGRAPHY AND MR IMAGING | 260 | ||
| MAMMOGRAPHY VERSUS MR IMAGING | 261 | ||
| POTENTIAL APPLICATIONS OF CONTRAST-ENHANCED MAMMOGRAPHY | 263 | ||
| SUMMARY | 263 | ||
| REFERENCES | 263 | ||
| Use of Breast-Specific PET Scanners and Comparison with MR Imaging | 265 | ||
| Key points | 265 | ||
| INTRODUCTION | 265 | ||
| BREAST-SPECIFIC PET DEVICES | 265 | ||
| IMAGING PROTOCOL AND RADIATION EXPOSURE | 267 | ||
| LOCAL EXTENT OF DISEASE | 268 | ||
| AXILLA | 269 | ||
| QUANTIFICATION | 269 | ||
| BACKGROUND 18F-2-DEOXY-2-FLUORO-D-GLUCOSE UPTAKE AND BREAST DENSITY | 269 | ||
| RESPONSE TO PRIMARY CHEMOTHERAPY | 270 | ||
| OTHER APPLICATIONS | 270 | ||
| SUMMARY | 270 | ||
| REFERENCES | 271 | ||
| Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment ... | 273 | ||
| Key points | 273 | ||
| INTRODUCTION | 273 | ||
| MOLECULAR BREAST IMAGING SYSTEMS | 274 | ||
| BREAST MR IMAGING AND MOLECULAR BREAST IMAGING IN BREAST CANCER SCREENING | 274 | ||
| BREAST MR IMAGING AND MOLECULAR BREAST IMAGING IN BREAST CANCER DIAGNOSIS | 275 | ||
| BREAST MR IMAGING AND MOLECULAR BREAST IMAGING IN BREAST CANCER STAGING | 276 | ||
| BREAST MR IMAGING AND MOLECULAR BREAST IMAGING FOR PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY | 277 | ||
| ADDITIONAL CONSIDERATIONS: BIOPSY, COST, RADIATION EXPOSURE, AVAILABILITY, AND PATIENT COMFORT | 278 | ||
| SUMMARY | 278 | ||
| REFERENCES | 278 | ||
| How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist | 281 | ||
| Key points | 281 | ||
| INTRODUCTION | 281 | ||
| MR Imaging Sensitivity | 282 | ||
| USE OF MR IMAGING IN PATIENTS WITH CANCER | 282 | ||
| Staging of the Primary Tumor | 282 | ||
| Contralateral Breast Cancer | 283 | ||
| Occult Primary Breast Cancer | 283 | ||
| Paget Disease | 284 | ||
| USE OF MR IMAGING IN PATIENTS WITHOUT CANCER | 284 | ||
| High-Risk Screening | 284 | ||
| DISADVANTAGES OF MR IMAGING | 285 | ||
| SUMMARY | 285 | ||
| REFERENCES | 286 | ||
| How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist | 289 | ||
| Key points | 289 | ||
| INTRODUCTION | 289 | ||
| Detection of Additional Disease in the Newly Diagnosed Patient with Breast Cancer | 290 | ||
| Tumor Vascularity and Ductal Carcinoma In Situ in Upstaging Disease | 290 | ||
| Breast Cancer Subtypes | 290 | ||
| Predicting Tumor Response | 290 | ||
| Staging Metastatic Disease | 291 | ||
| Breast Cancer Presenting as Unknown Primary Tumor | 291 | ||
| SUMMARY | 291 | ||
| REFERENCES | 292 | ||
| How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Radiation Oncologist | 295 | ||
| Key points | 295 | ||
| INTRODUCTION | 295 | ||
| EARLY-STAGE PATIENTS | 296 | ||
| Patient Selection for Accelerated Partial Breast Irradiation | 296 | ||
| Postoperative Delineation for Accelerated Partial Breast Irradiation or External Beam Boost | 297 | ||
| Defining the Preoperative Accelerated Partial Breast Irradiation Target | 298 | ||
| ADVANCED-STAGE PATIENTS | 299 | ||
| Identification of Locally Advanced Disease: Extensive Lymphatic Spread/Sternal Involvement | 299 | ||
| Identification of Locally Advanced Disease: Skin Thickening/Inflammatory Breast Cancer | 300 | ||
| RADIATION SIDE EFFECTS | 300 | ||
| SUMMARY | 301 | ||
| REFERENCES | 301 | ||
| American College of Radiology Accreditation, Performance Metrics, Reimbursement, and Economic Considerations in Breast MR I ... | 303 | ||
| Key points | 303 | ||
| INTRODUCTION | 303 | ||
| ACCREDITATION OVERVIEW | 303 | ||
| Background | 303 | ||
| Personnel | 304 | ||
| Technical Considerations | 304 | ||
| Peer Review | 304 | ||
| EVALUATING PERFORMANCE | 307 | ||
| Medical Outcome Audit | 307 | ||
| Performance Metrics | 308 | ||
| ECONOMIC CONSIDERATIONS | 309 | ||
| Cost-Effectiveness of Screening | 309 | ||
| Competing Modalities | 311 | ||
| Price Transparency | 311 | ||
| SUMMARY | 312 | ||
| REFERENCES | 312 |